Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
It has been well understood for years that biochemical recurrence (BCR) after radical prostatectomy does not always translate into systemic progression or necessarily lead to prostate cancer metastasis and death. The “natural history” of BCR is actually very variable.
Filed under: Living with Prostate Cancer, Management | Tagged: biochemical recurrence, natural history, outcome, prostatectomy, surgery | Leave a Comment »
The Centers for Medicare and Medicaid Services (CMS) proposed yesterday that there is sufficient and adequate evidence to conclude that the use of autologous cellular immunotherapy treatment — sipuleucel-T (Provenge®) – improves health outcomes for Medicare beneficiaries
Filed under: Management, Treatment | Tagged: CMS, coverage, Medicare, Provenge, sipuleucel-T | Leave a Comment »
A new study just published in Urology seems to confirm facts that have previously been identified in earlier studies of how men elect to get treated for localized prostate cancer in parts of the USA with a high proportion of African American residents and relatively low income levels.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: communication, decision-making, environment, race, rural, Treatment | Leave a Comment »
A new report in the Journal of Clinical Oncology suggests that — at least between 2000 and 2005 — “excessive PSA screening in elderly men with limited life expectancies” was a significant problem, and may remain so today.
Filed under: Diagnosis, Risk | Tagged: age, life expectancy, PSA, screening, testing | 2 Comments »
Previous research using so-called “genome-wide association studies” or GWAS have suggested that there may be as many as 30 different inherited prostate cancer genetic risk variants. What we don’t know much about yet is the relationships between specific genetic risk variants and the clinical outcomes of patients carrying those variants.
Filed under: Diagnosis, Management, Risk | Tagged: genetics, outcome, risk, SNP, variant | 5 Comments »
A new clinical trial being run by some of the investigators who originally coordinated the Prostate Cancer Prevention Trial is investigating whether a brief period of finasteride therapy (“finasteride challenge”) can help to distinuish between patients at serious risk for prostate cancer and those who don’t even need a biopsy.
Filed under: Diagnosis, Risk | Tagged: biopsy, challenge, Diagnosis, finasteride, PSA, risk | Leave a Comment »
As we get closer to the annual meeting of the American Society of Clinical Oncology (ASCO) — to be held at the beginning of June — the investor community is beginning its annual frenzy of speculation about exactly what new information will be presented at the meeting about development stage and marketed drugs.
Filed under: Drugs in development | Tagged: abiraterone, ASCO, investment, MDV3100 | 1 Comment »
First-line androgen deprivation therapy (ADT) for a man with metastatic prostate cancer has long been been either surgical or medical castration. In the case of medical castatration, the form of medication most commonly used since the mid to late 1980s has been an LHRH agonist (e.g., leuprolide acetate).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, antagonist, LHRH, suppression, testosterone | 2 Comments »
The U.S. Food & Drug Administration today approved ipilimumab (brand name Yervoy®) for the treatment of patients with metastatic melanoma (an aggressive form of skin cancer).
Filed under: Drugs in development, Management, Treatment | Tagged: ipilimumab, Yervoy | 8 Comments »
A new article in Lancet Oncology has reported that a mere 6 months of neoadjuvant hormone therapy, when combined with radiation therapy, cuts the risk of dying from locally advanced prostate cancer by 50 percent compared to radiation alone at 10 years of follow-up.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, hormone, neoadjuvant, outcome, radiation, survival | 10 Comments »
The Johns Hopkins Health Alerts yesterday issued a new summary of the up- and the downsides of the four “standard” treatments for localized prostate cancer: active surveillance, radical surgery, external beam radiation therapy, and brachytherapy (with permanent seed implantation).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: active surveillance, brachytherapy, cons, external beam radiation therapy, pros, surgery | 4 Comments »
The European Medicines Agency (EMA) has announced the launch of the EU Clinical Trials Register. This trial register will allow residents of the 27 EU member states, as well as Iceland, Liechtenstein, and Norway, to more easily find data about clinical trials of therapies for the management of prostate cancer (including new drugs).
Filed under: Uncategorized | Tagged: clinical trials, Europe, register | Leave a Comment »
Apparently, in the USA, there has been a small decrease in the incidence of PSA testing since the publication of data from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) and European Randomized Study of Screening for Prostate Cancer (ERSCP) trials back in March 2009.
Filed under: Diagnosis, Risk | Tagged: PSA, screening, testing | 4 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site